Cargando…

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Payne, Rebecca P., Longet, Stephanie, Austin, James A., Skelly, Donal T., Dejnirattisai, Wanwisa, Adele, Sandra, Meardon, Naomi, Faustini, Sian, Al-Taei, Saly, Moore, Shona C., Tipton, Tom, Hering, Luisa M., Angyal, Adrienn, Brown, Rebecca, Nicols, Alexander R., Gillson, Natalie, Dobson, Susan L., Amini, Ali, Supasa, Piyada, Cross, Andrew, Bridges-Webb, Alice, Reyes, Laura Silva, Linder, Aline, Sandhar, Gurjinder, Kilby, Jonathan A., Tyerman, Jessica K., Altmann, Thomas, Hornsby, Hailey, Whitham, Rachel, Phillips, Eloise, Malone, Tom, Hargreaves, Alexander, Shields, Adrian, Saei, Ayoub, Foulkes, Sarah, Stafford, Lizzie, Johnson, Sile, Wootton, Daniel G., Conlon, Christopher P., Jeffery, Katie, Matthews, Philippa C., Frater, John, Deeks, Alexandra S., Pollard, Andrew J., Brown, Anthony, Rowland-Jones, Sarah L., Mongkolsapaya, Juthathip, Barnes, Eleanor, Hopkins, Susan, Hall, Victoria, Dold, Christina, Duncan, Christopher J.A., Richter, Alex, Carroll, Miles, Screaton, Gavin, de Silva, Thushan I., Turtle, Lance, Klenerman, Paul, Dunachie, Susanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519781/
https://www.ncbi.nlm.nih.gov/pubmed/34735795
http://dx.doi.org/10.1016/j.cell.2021.10.011
_version_ 1784584523761057792
author Payne, Rebecca P.
Longet, Stephanie
Austin, James A.
Skelly, Donal T.
Dejnirattisai, Wanwisa
Adele, Sandra
Meardon, Naomi
Faustini, Sian
Al-Taei, Saly
Moore, Shona C.
Tipton, Tom
Hering, Luisa M.
Angyal, Adrienn
Brown, Rebecca
Nicols, Alexander R.
Gillson, Natalie
Dobson, Susan L.
Amini, Ali
Supasa, Piyada
Cross, Andrew
Bridges-Webb, Alice
Reyes, Laura Silva
Linder, Aline
Sandhar, Gurjinder
Kilby, Jonathan A.
Tyerman, Jessica K.
Altmann, Thomas
Hornsby, Hailey
Whitham, Rachel
Phillips, Eloise
Malone, Tom
Hargreaves, Alexander
Shields, Adrian
Saei, Ayoub
Foulkes, Sarah
Stafford, Lizzie
Johnson, Sile
Wootton, Daniel G.
Conlon, Christopher P.
Jeffery, Katie
Matthews, Philippa C.
Frater, John
Deeks, Alexandra S.
Pollard, Andrew J.
Brown, Anthony
Rowland-Jones, Sarah L.
Mongkolsapaya, Juthathip
Barnes, Eleanor
Hopkins, Susan
Hall, Victoria
Dold, Christina
Duncan, Christopher J.A.
Richter, Alex
Carroll, Miles
Screaton, Gavin
de Silva, Thushan I.
Turtle, Lance
Klenerman, Paul
Dunachie, Susanna
author_facet Payne, Rebecca P.
Longet, Stephanie
Austin, James A.
Skelly, Donal T.
Dejnirattisai, Wanwisa
Adele, Sandra
Meardon, Naomi
Faustini, Sian
Al-Taei, Saly
Moore, Shona C.
Tipton, Tom
Hering, Luisa M.
Angyal, Adrienn
Brown, Rebecca
Nicols, Alexander R.
Gillson, Natalie
Dobson, Susan L.
Amini, Ali
Supasa, Piyada
Cross, Andrew
Bridges-Webb, Alice
Reyes, Laura Silva
Linder, Aline
Sandhar, Gurjinder
Kilby, Jonathan A.
Tyerman, Jessica K.
Altmann, Thomas
Hornsby, Hailey
Whitham, Rachel
Phillips, Eloise
Malone, Tom
Hargreaves, Alexander
Shields, Adrian
Saei, Ayoub
Foulkes, Sarah
Stafford, Lizzie
Johnson, Sile
Wootton, Daniel G.
Conlon, Christopher P.
Jeffery, Katie
Matthews, Philippa C.
Frater, John
Deeks, Alexandra S.
Pollard, Andrew J.
Brown, Anthony
Rowland-Jones, Sarah L.
Mongkolsapaya, Juthathip
Barnes, Eleanor
Hopkins, Susan
Hall, Victoria
Dold, Christina
Duncan, Christopher J.A.
Richter, Alex
Carroll, Miles
Screaton, Gavin
de Silva, Thushan I.
Turtle, Lance
Klenerman, Paul
Dunachie, Susanna
author_sort Payne, Rebecca P.
collection PubMed
description Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4(+) T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.
format Online
Article
Text
id pubmed-8519781
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cell Press
record_format MEDLINE/PubMed
spelling pubmed-85197812021-10-18 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine Payne, Rebecca P. Longet, Stephanie Austin, James A. Skelly, Donal T. Dejnirattisai, Wanwisa Adele, Sandra Meardon, Naomi Faustini, Sian Al-Taei, Saly Moore, Shona C. Tipton, Tom Hering, Luisa M. Angyal, Adrienn Brown, Rebecca Nicols, Alexander R. Gillson, Natalie Dobson, Susan L. Amini, Ali Supasa, Piyada Cross, Andrew Bridges-Webb, Alice Reyes, Laura Silva Linder, Aline Sandhar, Gurjinder Kilby, Jonathan A. Tyerman, Jessica K. Altmann, Thomas Hornsby, Hailey Whitham, Rachel Phillips, Eloise Malone, Tom Hargreaves, Alexander Shields, Adrian Saei, Ayoub Foulkes, Sarah Stafford, Lizzie Johnson, Sile Wootton, Daniel G. Conlon, Christopher P. Jeffery, Katie Matthews, Philippa C. Frater, John Deeks, Alexandra S. Pollard, Andrew J. Brown, Anthony Rowland-Jones, Sarah L. Mongkolsapaya, Juthathip Barnes, Eleanor Hopkins, Susan Hall, Victoria Dold, Christina Duncan, Christopher J.A. Richter, Alex Carroll, Miles Screaton, Gavin de Silva, Thushan I. Turtle, Lance Klenerman, Paul Dunachie, Susanna Cell Article Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4(+) T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol. Cell Press 2021-11-11 /pmc/articles/PMC8519781/ /pubmed/34735795 http://dx.doi.org/10.1016/j.cell.2021.10.011 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Payne, Rebecca P.
Longet, Stephanie
Austin, James A.
Skelly, Donal T.
Dejnirattisai, Wanwisa
Adele, Sandra
Meardon, Naomi
Faustini, Sian
Al-Taei, Saly
Moore, Shona C.
Tipton, Tom
Hering, Luisa M.
Angyal, Adrienn
Brown, Rebecca
Nicols, Alexander R.
Gillson, Natalie
Dobson, Susan L.
Amini, Ali
Supasa, Piyada
Cross, Andrew
Bridges-Webb, Alice
Reyes, Laura Silva
Linder, Aline
Sandhar, Gurjinder
Kilby, Jonathan A.
Tyerman, Jessica K.
Altmann, Thomas
Hornsby, Hailey
Whitham, Rachel
Phillips, Eloise
Malone, Tom
Hargreaves, Alexander
Shields, Adrian
Saei, Ayoub
Foulkes, Sarah
Stafford, Lizzie
Johnson, Sile
Wootton, Daniel G.
Conlon, Christopher P.
Jeffery, Katie
Matthews, Philippa C.
Frater, John
Deeks, Alexandra S.
Pollard, Andrew J.
Brown, Anthony
Rowland-Jones, Sarah L.
Mongkolsapaya, Juthathip
Barnes, Eleanor
Hopkins, Susan
Hall, Victoria
Dold, Christina
Duncan, Christopher J.A.
Richter, Alex
Carroll, Miles
Screaton, Gavin
de Silva, Thushan I.
Turtle, Lance
Klenerman, Paul
Dunachie, Susanna
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
title Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
title_full Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
title_fullStr Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
title_full_unstemmed Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
title_short Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
title_sort immunogenicity of standard and extended dosing intervals of bnt162b2 mrna vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519781/
https://www.ncbi.nlm.nih.gov/pubmed/34735795
http://dx.doi.org/10.1016/j.cell.2021.10.011
work_keys_str_mv AT paynerebeccap immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT longetstephanie immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT austinjamesa immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT skellydonalt immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT dejnirattisaiwanwisa immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT adelesandra immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT meardonnaomi immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT faustinisian immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT altaeisaly immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT mooreshonac immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT tiptontom immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT heringluisam immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT angyaladrienn immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT brownrebecca immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT nicolsalexanderr immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT gillsonnatalie immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT dobsonsusanl immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT aminiali immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT supasapiyada immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT crossandrew immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT bridgeswebbalice immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT reyeslaurasilva immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT linderaline immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT sandhargurjinder immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT kilbyjonathana immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT tyermanjessicak immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT altmannthomas immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT hornsbyhailey immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT whithamrachel immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT phillipseloise immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT malonetom immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT hargreavesalexander immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT shieldsadrian immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT saeiayoub immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT foulkessarah immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT staffordlizzie immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT johnsonsile immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT woottondanielg immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT conlonchristopherp immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT jefferykatie immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT matthewsphilippac immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT fraterjohn immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT deeksalexandras immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT pollardandrewj immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT brownanthony immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT rowlandjonessarahl immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT mongkolsapayajuthathip immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT barneseleanor immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT hopkinssusan immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT hallvictoria immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT doldchristina immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT duncanchristopherja immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT richteralex immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT carrollmiles immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT screatongavin immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT desilvathushani immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT turtlelance immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT klenermanpaul immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT dunachiesusanna immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine
AT immunogenicityofstandardandextendeddosingintervalsofbnt162b2mrnavaccine